Crism TherapeuticsLSE:CRTX +2.38%38 EV-to-FCF is -3.62 as of Jul. 07, 2026. GuruFocus rates LSE:CRTX with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 329 Biotechnology companies, Crism Therapeutics ranks worse than 303951.06% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Crism Therapeutics's Enterprise Value is £7.23 Mil.
Crism Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £-2.00 Mil. Therefore, Crism Therapeutics's EV-to-FCF for today is -3.62.
The historical rank and industry rank for Crism Therapeutics's EV-to-FCF or its related term are showing as below:
LSE:CRTX'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.7 Med: -2.6 Max: -0.84
Current: -3.52
During the past 13 years, the highest EV-to-FCF of Crism Therapeutics was -0.84. The lowest was -6.70. And the median was -2.60.
LSE:CRTX's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 16.38
vs LSE:CRTX: -3.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Crism Therapeutics's PE Ratio (TTM) for today is calculated as:
Crism Therapeutics's share price for today is £0.1075.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Crism Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Crism Therapeutics EV-to-FCF Related Terms
Crism Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Crism Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CRTX vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Crism Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crism Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crism Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Crism Therapeutics's EV-to-FCF falls into.
Crism Therapeutics's current Enterprise Value is £7.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Crism Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £-2.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crism Therapeutics (LSE:CRTX) has a EV-to-FCF of -3.62 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Crism Therapeutics and its competitors. According to the industry distribution chart, Crism Therapeutics ranks #999999 out of 329 companies in the Biotechnology industry.
Is Crism Therapeutics' EV-to-FCF too high?
Crism Therapeutics' current EV-to-FCF is -3.62. Based on the distribution chart, Crism Therapeutics ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crism Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Crism Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Crism Therapeutics ranks #999999 out of 329 companies for EV-to-FCF. This places Crism Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.38, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Crism Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crism Therapeutics's current EV-to-FCF is -3.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crism Therapeutics stock overvalued right now?
Crism Therapeutics (LSE:CRTX) has a current EV-to-FCF of -3.62. The current EV-to-FCF is -3.62. Crism Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Crism Therapeutics (LSE:CRTX), the current EV-to-FCF is -3.62 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
38GF Score
Get the complete analysis for LSE:CRTX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CRTX has been successfully added to your 
